GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)

Launched by AHS CANCER CONTROL ALBERTA · Jan 17, 2025

Keywords

ClinConnect Summary

This clinical trial, called CLIC-YYC-GPNMB-02, is investigating a new treatment for a rare cancer called alveolar soft part sarcoma (ASPS). The treatment involves using a special type of immune cells, known as T-cells, that are modified to specifically target cancer cells expressing a protein called GPNMB. This trial is designed for a single patient who has progressive metastatic ASPS and has run out of other treatment options.

To be eligible for this trial, the patient must be between the ages of 65 and 74, must have good organ function, and must complete an informed consent form. However, individuals with active infections, those who are pregnant, or those who are nursing cannot participate. Since the trial is not yet recruiting participants, more information about what the patient can expect during treatment will be provided once it begins. This trial represents a hope for patients with limited treatment choices, aiming to explore personalized cell therapy that targets their specific cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Completion of Informed Consent Form
• • Adequate organ function, defined as creatinine clearance \>30 ml/min and LVEF \>45%.
• Exclusion Criteria:
• • Any active uncontrolled infection, pregnancy or nursing.